|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. doi: 10.3322/caac.21492.
|
|
2
|
Grivennikov SI: Insflammation and
colorectal cancer: Colitis-associated neoplasia. Semin
Immunopathol. 35:229–244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ordas I, Eckmann L, Talamini M, Baumgart
DC and Sandborn WJ: Ulcerative colitis. Lancet. 380:1606–1619.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Francescone R, Hou V and Grivennikov SI:
Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis.
21:409–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Neurath MF: Cytokines in inflammatory
bowel disease. Nat Rev Immunol. 14:329–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Toiyama Y, Okugawa Y, Tanaka K, Araki T,
Uchida K, Hishida A, Uchino M, Ikeuchi H, Hirota S, Kusunoki M, et
al: A panel of methylated microRNA biomarkers for identifying
high-risk patients with ulcerative Colitis-associated colorectal
cancer. Gastroenterology. 153:1634–1646. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Antoniou E, Margonis GA, Angelou A,
Zografos GC and Pikoulis E: Cytokine networks in animal models of
colitis-associated cancer. Anticancer Res. 35:19–24.
2015.PubMed/NCBI
|
|
8
|
Neurath MF and Finotto S: IL-9 signaling
as key driver of chronic inflammation in mucosal immunity. Cytokine
Growth Factor Rev. 29:93–99. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roy DN and Goswami R: IL-9 signaling
Pathway: An update. Methods Mol Biol. 1585:37–50. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goswami R and Kaplan MH: A brief history
of IL-9. J Immunol. 186:3283–3288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gerlach K, Hwang Y, Nikolaev A, Atreya R,
Dornhoff H, Steiner S, Lehr HA, Wirtz S, Vieth M, Waisman A, et al:
TH9 cells that express the transcription factor PU.1 drive T
cell-mediated colitis via IL-9 receptor signaling in intestinal
epithelial cells. Nat Immunol. 15:676–686. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuttler F and Mai S: c-Myc, genomic
instability and disease. Genome Dyn. 1:171–190. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sipos F, Firneisz G and Muzes G:
Therapeutic aspects of c-MYC signaling in inflammatory and
cancerous colonic diseases. World J Gastroenterol. 22:7938–7950.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Farrell AS and Sears RC: MYC degradation.
Cold Spring Harb Perspect Med. 4:doi: 10.1101/cshperspect.a014365.
PubMed/NCBI
|
|
15
|
Robles AI, Traverso G, Zhang M, Roberts
NJ, Khan MA, Joseph C, Lauwers GY, Selaru FM, Popoli M, Pittman ME,
et al: Whole-exome sequencing analyses of inflammatory bowel
disease-associated colorectal cancers. Gastroenterology.
150:931–943. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qie S and Diehl JA: Cyclin D1, cancer
progression, and opportunities in cancer treatment. J Mol Med
(Berl). 94:1313–1326. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kopparapu PK, Boorjian SA, Robinson BD,
Downes M, Gudas LJ, Mongan NP and Persson JL: Expression of cyclin
d1 and its association with disease characteristics in bladder
cancer. Anticancer Res. 33:5235–5242. 2013.PubMed/NCBI
|
|
18
|
Mudaliar K, Tetzlaff MT, Duvic M, Ciurea
A, Hymes S, Milton DR, Tsai KY, Prieto VG, Torres-Cabala CA and
Curry JL: BRAF inhibitor therapy-associated melanocytic lesions
lack the BRAF V600E mutation and show increased levels of cyclin D1
expression. Hum Pathol. 50:79–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ok CY, Xu-Monette ZY, Tzankov A, O'Malley
DP, Montes-Moreno S, Visco C, Møller MB, Dybkaer K, Orazi A, Zu Y,
et al: Prevalence and clinical implications of cyclin D1 expression
in diffuse large B-cell lymphoma (DLBCL) treated with
immunochemotherapy: A report from the International DLBCL
Rituximab-CHOP Consortium Program. Cancer. 120:1818–1829. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peurala E, Koivunen P, Haapasaari KM,
Bloigu R and Jukkola-Vuorinen A: The prognostic significance and
value of cyclin D1, CDK4 and p16 in human breast cancer. Breast
Cancer Res. 15:R52013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Truran PP, Johnson SJ, Bliss RD, Lennard
TW and Aspinall SR: Parafibromin, galectin-3, PGP9.5, Ki67, and
cyclin D1: Using an immunohistochemical panel to aid in the
diagnosis of parathyroid cancer. World J Surg. 38:2845–2854. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao W, Hu JX, Hao RM, Zhang Q, Guo JQ, Li
YJ, Xie N, Liu LY, Wang PY, Zhang C and Xie SY: Induction of
microRNAlet7a inhibits lung adenocarcinoma cell growth by
regulating cyclin D1. Oncol Rep. 40:1843–1854. 2018.PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koch S, Sopel N and Finotto S: Th9 and
other IL-9-producing cells in allergic asthma. Semin Immunopathol.
39:55–68. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fischer M, Bijman M, Molin D, Cormont F,
Uyttenhove C, van Snick J, Sundström C, Enblad G and Nilsson G:
Increased serum levels of interleukin-9 correlate to negative
prognostic factors in Hodgkin's lymphoma. Leukemia. 17:2513–2516.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lemoli RM, Fortuna A, Tafuri A, Fogli M,
Amabile M, Grande A, Ricciardi MR, Petrucci MT, Bonsi L, Bagnara G,
et al: Interleukin-9 stimulates the proliferation of human myeloid
leukemic cells. Blood. 87:3852–3859. 1996.PubMed/NCBI
|
|
27
|
Weigmann B and Neurath MF: Th9 cells in
inflammatory bowel diseases. Semin Immunopathol. 39:89–95. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ye ZJ, Zhou Q, Yin W, Yuan ML, Yang WB,
Xiong XZ, Zhang JC and Shi HZ: Differentiation and immune
regulation of IL-9-producing CD4+ T cells in malignant pleural
effusion. Am J Respir Crit Care Med. 186:1168–1179. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Casey SC, Baylot V and Felsher DW: The MYC
oncogene is a global regulator of the immune response. Blood.
131:2007–2015. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jin M, Inoue S, Umemura T, Moriya J,
Arakawa M, Nagashima K and Kato H: Cyclin D1, p16 and
retinoblastoma gene product expression as a predictor for prognosis
in non-small cell lung cancer at stages I and II. Lung cancer.
34:207–218. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shamma A, Doki Y, Shiozaki H, Tsujinaka T,
Yamamoto M, Inoue M, Yano M and Monden M: Cyclin D1 overexpression
in esophageal dysplasia: A possible biomarker for carcinogenesis of
esophageal squamous cell carcinoma. Int J Oncol. 16:261–266.
2000.PubMed/NCBI
|
|
32
|
Bartkova J, Lukas J, Muller H, Strauss M,
Gusterson B and Bartek J: Abnormal patterns of D-type cyclin
expression and G1 regulation in human head and neck cancer. Cancer
Res. 55:949–956. 1995.PubMed/NCBI
|
